1060 related articles for article (PubMed ID: 7784479)
1. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
2. Contribution of bradykinin to the cardiovascular effects of ramipril.
Linz W; Wiemer G; Schölkens BA
J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
[TBL] [Abstract][Full Text] [Related]
3. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
Linz W; Schölkens BA
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
[TBL] [Abstract][Full Text] [Related]
4. Local inhibition of bradykinin degradation in ischemic hearts.
Linz W; Martorana PA; Schölkens BA
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
[TBL] [Abstract][Full Text] [Related]
5. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
Linz W; Wiemer G; Schaper J; Zimmermann R; Nagasawa K; Gohlke P; Unger T; Schölkens BA
Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):89-97. PubMed ID: 7494560
[TBL] [Abstract][Full Text] [Related]
7. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
Linz W; Wiemer G; Schölkens BA
Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
[TBL] [Abstract][Full Text] [Related]
8. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
Schölkens BA; Linz W
Clin Physiol Biochem; 1990; 8 Suppl 1():33-43. PubMed ID: 2147878
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
Linz W; Wiemer G; Schölkens BA
Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
[TBL] [Abstract][Full Text] [Related]
11. Kinin-related effects of angiotensin-converting enzyme inhibition.
Bönner G
Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
[TBL] [Abstract][Full Text] [Related]
12. [Do kinins have significance for the antihypertensive effect of angiotensin-converting enzyme inhibitors?].
Bönner G
Z Kardiol; 1988; 77 Suppl 3():23-7. PubMed ID: 3062958
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
[TBL] [Abstract][Full Text] [Related]
14. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
15. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
Nolly H; Miatello R; Damiani MT; Abate CD
Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
[TBL] [Abstract][Full Text] [Related]
16. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
Gohlke P; Linz W; Schölkens B; Van Even P; Martorana P; Unger T
Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
[TBL] [Abstract][Full Text] [Related]
17. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.
Linz W; Wiemer G; Schölkens BA
J Mol Cell Cardiol; 1992 Aug; 24(8):909-19. PubMed ID: 1331474
[TBL] [Abstract][Full Text] [Related]
18. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
19. Kinin- and non-kinin-mediated interactions of converting enzyme inhibitors with vasoactive hormones.
Kramer HJ; Glänzer K; Meyer-Lehnert H; Mohaupt M; Predel HG
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S91-8. PubMed ID: 1697369
[TBL] [Abstract][Full Text] [Related]
20. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
Schalekamp MA; Derkx FH; van den Meiracker AH
J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
